Ketamine Therapy for Mental Health: What It Is, How It Works, and Who It's For

Ketamine is an NMDA (N-methyl-D-aspartate) glutamate receptor antagonist. That sentence is worth unpacking, because it explains everything about why it works differently from SSRIs and SNRIs.

Standard antidepressants — SSRIs, SNRIs, TCAs, MAOIs — target the monoamine neurotransmitter systems: serotonin, norepinephrine, dopamine. The monoamine hypothesis of depression held that depression was caused by a deficiency of these neurotransmitters. That hypothesis has been substantially complicated over the last two decades — monoamine levels alone do not explain depression, which is why some patients respond to SSRIs and others don't, and why 30–40% of people never reach full remission despite multiple adequate trials.

Glutamate is the most abundant excitatory neurotransmitter in the central nervous system, and it plays a central role in synaptic plasticity — the brain's ability to strengthen and form new neural connections. Chronic stress and depression are associated with impaired synaptic plasticity, particularly in the prefrontal cortex and hippocampus. Ketamine, by blocking NMDA receptors, triggers a cascade of downstream effects that restore this plasticity rapidly.

Original use: as a dissociative anesthetic in surgery and trauma medicine. Still used as a veterinary anesthetic. Still used in procedural sedation for patients in whom other anesthetics are contraindicated. The psychiatric application is a repurposing of an existing drug with a well-understood safety profile.

IV Ketamine Infusions (Off-Label)

Intravenous ketamine infusions have the longest clinical track record in psychiatry and the most published research. They are administered in a clinical setting (a ketamine clinic, anesthesiology practice, or infusion center), typically over 40–60 minutes per session, with continuous monitoring. The standard induction protocol is 6 infusions over 2–3 weeks.

Critically: IV ketamine for psychiatric indications is off-label. The FDA has not approved ketamine itself for depression — only esketamine (a related compound) has FDA approval. This has significant insurance implications.

Esketamine / Spravato (FDA-Approved)

Esketamine (brand name Spravato) is the S-enantiomer of ketamine — a closely related compound with similar mechanism. It was FDA-approved in March 2019 as an intranasal spray for treatment-resistant depression, and in 2020 received additional approval for major depressive disorder with acute suicidal ideation or behavior. Spravato is the only FDA-approved ketamine compound for psychiatric use.

Administration is under a healthcare provider's supervision in a certified healthcare setting — Spravato cannot be taken home. The REMS (Risk Evaluation and Mitigation Strategy) program requires that patients remain at the facility for at least 2 hours after each dose for monitoring. Typical protocol: twice weekly for 4 weeks (induction), then once weekly for 4 weeks (consolidation), then once weekly or biweekly for maintenance.

The most striking clinical feature of ketamine is speed. Standard antidepressants typically require 4–6 weeks to produce meaningful clinical response — a delay that reflects the gradual downstream effects on gene expression and receptor density. Ketamine produces antidepressant effects within hours of administration in many patients. This speed is not a marketing claim; it is a documented pharmacological phenomenon with a specific mechanism.

AMPA Receptor Potentiation

When ketamine blocks NMDA receptors, the glutamate that would have bound to NMDA receptors instead activates AMPA receptors more intensely. This AMPA receptor stimulation initiates a downstream signaling cascade that leads to the antidepressant effects.

BDNF Release and Synaptogenesis

AMPA receptor activation triggers the release of BDNF (Brain-Derived Neurotrophic Factor), a protein critical for neuronal survival, growth, and synaptogenesis — the formation of new synaptic connections. Chronic depression is associated with reduced BDNF levels and synaptic loss, particularly in the prefrontal cortex and hippocampus. Ketamine rapidly reverses this: within hours of administration, preclinical models show new synaptic spine formation in these regions. The metaphor that has gained traction is “rapid synaptogenesis” — the brain literally growing new connections at a measurable rate following ketamine administration.

This mechanism explains not just the speed but the durability of response — and also why some patients need ongoing maintenance treatment. The synaptogenesis is real but reversible without continued input.

Treatment-Resistant Depression

The primary indication. Conventionally defined as failure to respond to two or more adequate antidepressant trials (adequate = appropriate dose for an appropriate duration, typically 6–8 weeks at therapeutic dose). By some estimates, 30% of people with major depression meet criteria for treatment resistance. Response rates in this population with ketamine are approximately 50–70%, which substantially exceeds what is typically achievable with further antidepressant trials.

MDD with Acute Suicidal Ideation

This is the unique Spravato FDA indication added in 2020. Ketamine has demonstrated rapid antisuicidal effects — reductions in active suicidal ideation within hours — that no other antidepressant achieves. For patients in acute psychiatric crises, this speed profile is clinically invaluable. It is not a first-line intervention for all suicidal patients, but it represents an option for crisis situations where the 4–6 week SSRI timeline is incompatible with immediate safety.

Bipolar Depression (With Caveats)

Ketamine has been studied in bipolar depression with generally positive findings for acute depressive episodes. The caveats: the risk of mood destabilization (hypomanic or manic switch) is real, though lower than with standard antidepressants. Ketamine in bipolar depression should typically be done in coordination with a mood stabilizer and with careful monitoring. It is not first-line for bipolar depression but is a reasonable option for treatment-resistant bipolar depressive episodes under specialist supervision.

PTSD — Emerging Evidence

Early research on ketamine for PTSD shows promising results, likely related to its ability to disrupt fear memory reconsolidation (NMDA receptor blockade during memory reactivation can interfere with the restabilization of traumatic memories). This is an active area of research, not yet standard practice, and should be distinguished from ketamine-assisted psychotherapy for PTSD, which is a related but distinct intervention.

Ketamine produces dissociative experiences during administration — alterations in perception, sense of self, and experience of time. Some patients report visual or auditory phenomena. These are expected, dose-related, and transient — they typically resolve within 30–60 minutes after IV administration.

This is not recreational intoxication in a clinical context. The dissociative experience is a direct pharmacological effect that accompanies the therapeutic mechanism. Many patients find it unusual but tolerable; some find it the most interesting experience they've had in treatment; others find it uncomfortable and require reassurance beforehand. None of this predicts clinical response — the antidepressant effect is not dependent on the degree of dissociation experienced.

Typical Protocols

• IV ketamine: 6 infusions over 2–3 weeks (induction). Sessions typically 40–60 minutes. Dose typically 0.5 mg/kg over 40 minutes. Patients cannot drive afterward; a driver is required.
• Spravato (esketamine): Twice weekly for 4 weeks (induction), then once weekly for 4 weeks (consolidation), then once weekly or every other week (maintenance). Self-administered under observation; 2-hour monitoring period required.

Duration of Response and Maintenance

This is the central challenge with ketamine: response rates are high (50–70%), but the duration of response is variable and often limited without continued treatment. Many patients experience relief lasting weeks to a few months after an induction series. Without maintenance sessions, many eventually relapse. Ongoing research is exploring oral ketamine (lozenges or nasal spray for home maintenance) as a lower-cost option, but the evidence base is still developing. Patients and providers should have a direct conversation about the maintenance plan before starting induction.

Ketamine is not appropriate for everyone. Contraindications include:

• Uncontrolled hypertension — ketamine transiently increases blood pressure and heart rate; patients with cardiovascular disease require careful pre-treatment evaluation
• Active psychosis or schizophrenia spectrum disorder — ketamine's NMDA antagonism can exacerbate psychotic symptoms; it is generally contraindicated in active psychosis
• History of ketamine misuse or addiction — while addiction risk in therapeutic settings is low, a history of ketamine misuse is a contraindication
• Pregnancy — insufficient safety data; generally avoided
• Unstable cardiovascular disease — requires careful screening

Relative contraindications (require careful evaluation): active substance use disorder, current hyperthyroidism, elevated intracranial pressure, and severe personality disorders with dissociation history (the dissociative effect of ketamine may be destabilizing rather than therapeutic).

Spravato (Esketamine)

Because Spravato is FDA-approved, it has a pathway to insurance coverage — including Medicare and Medicaid in many states — for qualifying indications (treatment-resistant depression; MDD with acute suicidal ideation). Prior authorization is almost always required. Coverage varies significantly by insurer and plan. Janssen (the manufacturer) offers a patient assistance program for qualifying patients. The REMS requirement that administration happens in a certified setting adds an administrative layer but also ensures oversight.

IV Ketamine

IV ketamine for psychiatric indications is largely out-of-pocket because it is off-label. Typical cost: $400–$800 per infusion, with most induction series requiring 6 infusions. Total induction cost: $2,400–$4,800, not including provider evaluation, pre-treatment workup, or maintenance sessions. Some infusion centers offer payment plans. This cost barrier is real and should be part of the treatment planning conversation.

The value framing for patients considering the cost: ketamine is not competing with a $25/month generic antidepressant — it is competing with years of ongoing treatment for depression that has not responded to multiple trials, the productivity losses associated with untreated depression, and the cost of alternative interventions like TMS (also expensive and time-intensive) or ECT (often covered but requires hospitalization or intensive outpatient).

Research increasingly supports that ketamine works better with psychotherapy support than without it. The mechanism: the post-ketamine window (24–72 hours after infusion) is characterized by enhanced neural plasticity — the brain is in a state of heightened openness to learning and change. Psychotherapy delivered during this window — working on cognitions, exploring patterns, processing difficult material — may consolidate the neuroplastic changes more effectively than the drug alone.

Integration therapy, as it is commonly called, involves preparation before sessions and processing after them — helping the patient contextualize the experience, identify insights, and translate them into behavioral change. This is distinct from standard psychotherapy and from ketamine-assisted psychotherapy (KAP).

Ketamine-Assisted Psychotherapy (KAP) vs. Medical Infusions

These are two distinct clinical models that are often conflated:

• Medical infusions — ketamine administered by an anesthesiologist or physician for its direct antidepressant effect, without psychotherapy being a formal component. The most common model in ketamine clinics.
• Ketamine-Assisted Psychotherapy (KAP) — ketamine administered in conjunction with active psychotherapy, often using a lower dose that produces a lighter dissociative state and allows the patient to be more verbally engaged. Typically involves both a prescribing provider and a therapist, sometimes with the therapist present during the session. More common in mental health practice contexts than in anesthesia-based clinics.

KAP has stronger theoretical support for durability of response but is less widely available and more expensive. Medical infusions are more accessible and have stronger evidence in the literature for acute antidepressant effects.

Addiction and Misuse Potential

Ketamine does have abuse potential — it is a Schedule III controlled substance. In recreational settings, misuse is well documented. In therapeutic settings, addiction is rare. The supervised-administration, structured-protocol model used in clinical practice is fundamentally different from recreational use in terms of dosing, frequency, and context. That said, patients with a history of substance use disorders warrant careful pre-treatment screening, and the ketamine conversation should address this directly.

Bladder Toxicity

Ketamine-induced uropathy — inflammation and fibrosis of the bladder and urinary tract — is a documented complication of chronic, high-frequency ketamine use. It is primarily observed in recreational users who take ketamine daily at high doses. In therapeutic protocols (6 infusions over 2–3 weeks, or even maintenance at once-weekly or biweekly), the cumulative dose exposure is orders of magnitude lower than the doses associated with bladder damage. Bladder toxicity should be disclosed as a risk but contextualized accurately: it is a dose-dependent complication primarily associated with recreational patterns of use.

What to Look For

• A pre-treatment psychiatric evaluation — a reputable provider evaluates whether ketamine is appropriate, reviews your psychiatric history, and screens for contraindications. If a clinic will administer ketamine without a thorough psychiatric assessment, that is a red flag.
• Medical supervision during administration — IV ketamine requires continuous vital sign monitoring. Spravato requires the REMS-mandated 2-hour observation.
• Coordination with your existing psychiatric care — the best ketamine outcomes happen when the ketamine clinic is in communication with your prescribing provider and therapist, not operating as an isolated intervention.
• A clear maintenance plan — good providers discuss upfront what happens after the induction series, what the data suggests about response duration, and what options exist for maintenance.

Red Flags

• No psychiatric evaluation before treatment
• Guaranteed results (“ketamine cures depression”)
• Encouragement to discontinue existing psychiatric medications before consult with your prescriber
• No integration or follow-up support
• Unusually high treatment frequencies without clinical rationale
• Telehealth-only at-home ketamine without in-person evaluation (increasingly prevalent; evidence base is limited)

1. “Do I meet the clinical criteria for treatment-resistant depression, and is ketamine appropriate for my presentation?” — If your provider can't answer this clearly, ask for a referral to someone who can.
2. “Should I try Spravato (FDA-approved, covered by insurance) or IV ketamine (off-label, typically out-of-pocket)?” — The answer depends on your insurance, local availability, and clinical picture.
3. “What happens if it works — what does the maintenance plan look like, and what does it cost ongoing?” — This question is underasked and critically important for treatment planning.
4. “Will ketamine interact with my current psychiatric medications?” — Most psychiatric medications are compatible with ketamine, but benzodiazepines in particular can reduce the antidepressant effect. Your prescriber should review your full medication list.
5. “Should I pair this with psychotherapy, and if so, what kind?” — Evidence supports better outcomes with integration therapy. Ask about the specific model used.